

# Learner Notification

---

## Anticoagulation Forum

### Perioperative Management of Anticoagulation

Date of CE Release: 01-27-2022

Date of CE Expiration: 01-27-2024

Location: Online

### **Acknowledgement of Financial Commercial Support**

No financial commercial support was received for this educational activity.

### **Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

### **Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### **Joint Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Anticoagulation Forum. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physicians**

Amedco LLC designates this material for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Pharmacists**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

### **Nurses**

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

### **Objectives - After Attending This Program You Should Be Able To**

1. Explain significant differences between perioperative management of DOAC and warfarin, including the rationale for these differences
2. Determine if temporary interruption of anticoagulant therapy is needed through evaluation of factors, including bleeding and

thrombotic potential of the procedure and the patient

3. Develop safe, effective perioperative anticoagulation plans for DOAC and warfarin patients based on existing evidence and expert consensus

## Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

Name	Commercial Interest:Relationship
Arthur Allen	Janssen Pharmaceuticals, Alexion Pharmaceuticals:Speakers Bureau Boehringer-Ingelheim, BMS/Pfizer:Scientific/Medical Advisory Board Member
Allison Burnett	Pfizer:Scientific/Medical Advisory Board Member
Scott Kaatz	BMS, Osmosis research, Janssen, NIH:Research Grant Site Principal Investigator BMS, Janssen, Pfizer, Novartis, Portola/Alexion, CSL Behring, Gilead:Consultant
Bishoy Ragheb	NA
Andrea Van Beek	NA

## How to Get Your Certificate

1. Click on the **Perioperative Management of Anticoagulation** link.
2. Evaluate the meeting.
3. Print, download, or save your certificate for your records.